On March 23, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for small cell lung cancer.
The version 3.2021 update features modifications for supportive care and subsequent systemic therapy.
In the section for principles of supportive care, a bullet was added stating, “trilaciclib may be used as a prophylactic option to decrease the incidence of chemotherapy-induced myelosuppression when administered before (or G-CSF may be administered after) platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for extensive-stage small cell lung cancer.”
In addition, pembrolizumab was changed from a category 2A to a category 3 recommendation for subsequent systemic therapy in patients who relapse ≤6 months.—Janelle Bradley
